BRIEF published on 10/21/2025 at 18:54, 4 months 27 days ago Genetic validation of ApoA-I in sepsis by ABIONYX Pharma Innovative Therapies ABIONYX Pharma Sepsis Apolipoprotein AI Genetic Validation
PRESS RELEASE published on 10/21/2025 at 18:49, 4 months 27 days ago Inside Information / Other news releases ABIONYX Pharma announces groundbreaking genetic validation study published in NATURE confirming Apolipoprotein A-I (ApoA-I) causality in Sepsis, reshaping critical care medicine ABIONYX Pharma Sepsis Genetic Validation Study NATURE Publication Apolipoprotein A-I
BRIEF published on 10/06/2025 at 15:00, 5 months 11 days ago Threshold crossing by the Caisse des dépôts et consignations in ABIONYX PHARMA Voting Rights CDC Threshold Crossing Bpifrance ABIONYX
BRIEF published on 10/06/2025 at 14:56, 5 months 11 days ago Threshold Crossing by Bpifrance at ABIONYX PHARMA Voting Rights Actions Threshold Crossing Bpifrance ABIONYX Pharma
BRIEF published on 09/25/2025 at 20:21, 5 months 21 days ago ABIONYX Pharma: Financial results for the first half of 2025 Financial Results Research And Development Treasury France 2030 Plan ABIONYX Pharma
PRESS RELEASE published on 09/25/2025 at 20:16, 5 months 21 days ago Inside Information / News release on accounts, results ABIONYX Pharma announces its 2025 half-year financial results, including revenue of €2.1 million and ongoing initiatives in biotech innovation. Company receives government support for sepsis research Revenue Biotech Innovation ABIONYX Pharma 2025 Financial Results Sepsis Research
BRIEF published on 08/28/2025 at 18:56, 6 months 20 days ago ABIONYX Pharma 2025 half-year review Treasury Financial Support Turnover ABIONYX Pharma Semester 2025
PRESS RELEASE published on 08/28/2025 at 18:51, 6 months 20 days ago Inside Information / Other news releases ABIONYX Pharma provided an update on its activity and cash position for Q2 2025. Company's revenue, cash position, and government funding details revealed Revenue Cash Position Update Government Funding ABIONYX Pharma
BRIEF published on 08/27/2025 at 19:31, 6 months 21 days ago ABIONYX Pharma in talks for a strategic partnership in sepsis Strategic Partnership Innovative Therapies ABIONYX Pharma Sepsis CER-001
PRESS RELEASE published on 08/27/2025 at 19:26, 6 months 21 days ago Inside Information / Other news releases ABIONYX Pharma initiates discussions with a major sepsis player for strategic partnership, aiming to accelerate CER-001 development. Relevance of innovative technology validated Strategic Partnership Innovative Technology ABIONYX Pharma Sepsis CER-001
Published on 03/17/2026 at 13:30, 6 hours 40 minutes ago Hillcrest Energy Technologies Confirms ZVS PCS1000 Prototype on Track for June 2026
Published on 03/17/2026 at 13:30, 6 hours 40 minutes ago Namibia Critical Metals Welcomes Toyota Tsusho as Strategic Partner in the Lofdal Heavy Rare Earths Project
Published on 03/17/2026 at 13:00, 7 hours 10 minutes ago Avant Brands Announces Strategic Realignment of European Operations and Reclaims BLK MKT Brand Rights in Germany and Switzerland
Published on 03/17/2026 at 13:00, 7 hours 10 minutes ago High-Resolution Airborne Survey Completed at Music Valley HREE Project
Published on 03/17/2026 at 12:30, 7 hours 40 minutes ago Revival Gold Targets Underground Resource Growth With Drilling at Beartrack-Arnett Gold Project in Idaho
Published on 03/17/2026 at 17:58, 2 hours 12 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 03/17/2026 at 15:30, 4 hours 40 minutes ago Original-Research: Desert Gold Ventures Inc. (von GBC AG): Buy
Published on 03/17/2026 at 15:19, 4 hours 51 minutes ago Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group PLC
Published on 03/17/2026 at 07:00, 13 hours 10 minutes ago Invitation to the Extraordinary General Meeting of shareholders
Published on 03/16/2026 at 18:00, 1 day 2 hours ago Disclosure of trading in own shares from 09/03/2026 to 13/03/2026
Published on 03/16/2026 at 17:58, 1 day 2 hours ago Aéroports de Paris S.A - February 2026 traffic figures
Published on 03/16/2026 at 17:56, 1 day 2 hours ago Reporting on share buyback transactions carried out between March 9 and March 13, 2026
